复发性星形细胞瘤p16基因的研究  

A Study of p16 Gene in Recurrent Astrocytoma

作　　者：张刚利[1] 吉宏民[1] 张汉伟[1] 

机构地区：[1]山西省人民医院,山西太原030012

出　　处：《山西职工医学院学报》2005年第1期3-6,共4页Journal of Shanxi Medical College for Continuing Education

摘　　要：目的 :结合病理学分级 ,研究复发星形细胞瘤的p16基因异常 ,探讨p16基因在星形细胞瘤复发中的作用。方法 :采用复合PCR、PCR SSCP等方法 ,对 2 2例星形细胞瘤患者的原、复发标本进行基因缺失及点突变的检测。结果 :在全部 4 4个标本中发现纯合性缺失 14例 ,缺失率为 31.8% (14 /44 )。将Ⅰ和Ⅱ、Ⅲ和Ⅳ级分别合并后相比差异有显著性。发生p16基因缺失的病例 ,依其发生的时间先后分为三组。PCR SSCP检测 ,点突变发生率为 6 8% (3/44 )。结论 :星形细胞瘤在其恶性增殖中发生p16基因缺失 ,而基因缺失可能在维持其恶性表型中起重要作用。检测p16基因的缺失对判断星形细胞瘤的恶性转化有一定价值。点突变在星形细胞瘤进展中发生频率较低 。Objective:To evaluate the role of p16 gene in the recurrence of astrocytomas.Methods:Twenty-two pairs of astrocytomas were examined for alteration of p16 gene with multiple-PCR and PCR-SSCP methods.Results:In astrocytomas,multiple-PCR revealed 14 patients had homozygous deletions in tumor group,and deletion rate was 31.8%((14/44)).Deletion rate was significantly higher in high-grade astrocytomas than in low-grade group((P<0.01).)Analysis of 10 matched pairs astrocytomas and their subsequent recurrences identified three distinct groups:the recurrent tumors in group A showed p16 gene deletion while primary tumors didn't.In this group low-grade tumors ((GⅠ～)Ⅱ) had progressed to higher-grade tumors (GⅢ～Ⅳ);in group B,deletion of p16 gene was observed in both primary and recurrent tumors and histopathological grade sustained high grade (GⅢ～Ⅳ) upon recurrence;the primary tumors in group C had a p16 deletion.Upon recurrence,however,no deletion was detected;three samples in tumor group had mobility shift in their PCR-SSCP analysis,indicating point or subtle mutations have developed in those tumor cells ((3/44)).Conclusion:The deletion of p16 gene occurred in the process of progression of astrocytomas and gene deletion may have an important role in sustaining malignant phenotype.p16 gene deletion may suggest malignancy of astrocytomas.Point mutation may not be an important role in tumor progression.

关 键 词：复发性星形细胞瘤 PCR-SSCP检测 P16基因缺失 P16基因异常 病理学分级 复合PCR 纯合性缺失 点突变 恶性增殖 恶性表型 恶性转化 发生频率 缺失率 显著性 发生率 标本 

分 类 号：R730.264[医药卫生—肿瘤] R734.2[医药卫生—临床医学]